Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer.

[1] It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.

[citation needed] This drug was developed by Seattle Genetics, Inc.

The drug completed phase I clinical trials for renal cell carcinoma,[2] but development was discontinued in 2013.

[3] No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.